An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.
adverse event
baseline observation carried forward
CADTH Common Drug Review
confidence interval
chronic idiopathic urticaria
Chronic Urticaria Quality of Life Questionnaire
Dermatology Life Quality Index
electronic diary
EuroQol 5-Dimensions Questionnaire
immunoglobulin E
leukotriene receptor antagonist
minimal clinically important difference
omalizumab
serious adverse event
Urticaria Activity Score
Urticaria Activity Score over seven days
withdrawal due to adverse event
Weekly Itch Severity Score
Weekly Number of Hives Score
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
